Kilroy Realty’s stock dropped significantly over the last five years but has recently started to jump back up. The company struggled as many people stopped working in offices, leaving many of their buildings empty. Now, the business is trying to recover by turning some of its properties into labs for science companies to attract new renters.
What does it do?
Kilroy Realty is a mature real estate business that earns money by owning, developing, and leasing high-quality office and laboratory space to tech and life science companies. As a Real Estate Investment Trust (REIT), it buys or builds properties in concentrated West Coast clusters and signs long-term contracts with tenants who pay monthly rent and a share of operating costs. Its revenue flows directly from these lease agreements, which typically last several years and include annual rent increases. Customers keep paying because Kilroy’s buildings are in "trophy" locations with modern amenities that help companies attract top talent.
Where does revenue come from?
The vast majority of Kilroy’s revenue comes from base rent and expense reimbursements from its portfolio of office and life science buildings. It manages over 13 million square feet of space across four main regions: San Francisco, Los Angeles, San Diego, and Seattle. While traditional office space is still the largest segment, the company is actively shifting its mix toward life science laboratories to capture more stable demand from the biotech industry.
Revenue Breakdown
Who are its customers?
Kilroy Realty serves a concentrated group of large technology firms and growing life science companies that require specialized, premium workspaces. Its top tenants often include names like Adobe, Salesforce, and pharmaceutical giants, though its total portfolio occupancy ended 2025 at 81.6%. The company signed a record volume of new leases in the fourth quarter of 2025, but it is still working to fill the 18.4% of its space that remains vacant. It tracks its success through the "leased-to-economic occupancy" spread, which represents the rent it has signed but has not yet started collecting.
What gives it staying power?
Kilroy’s staying power comes from owning some of the most technologically advanced and environmentally sustainable buildings in land-constrained coastal markets. These "Class A" properties are difficult for competitors to build from scratch because of high costs and strict local zoning. However, this advantage is currently under pressure as remote work reduces the overall need for office space.
Where is it headed?
Kilroy is making a major strategic bet on the life science sector by acquiring and developing lab-ready buildings in San Diego’s Torrey Pines cluster. Management recently bought the Nautilus campus for $192 million to expand its footprint in one of the few markets where tenant demand remains strong. If this shift works, Kilroy will become less dependent on the volatile tech office market and more tied to the steady growth of biotech research.
The most important trend is that Kilroy is seeing a divergence between its steady revenue and a sharp decline in its actual earnings power. While annual revenue held steady at $1.11 billion in 2025, GAAP earnings are expected to fall by more than 80% next year as interest costs and empty buildings take their toll.
The quality of cash generation is currently under pressure because Kilroy must spend heavily on building improvements and tenant incentives to fill its empty spaces. Free cash flow turned negative in 2025, hitting minus $120 million, which reveals that the company is spending more on maintaining and developing its properties than it is bringing in from rent.
The balance sheet is managed with a moderate amount of debt, carrying a debt-to-equity ratio of 0.90, which provides some resilience but limits aggressive new spending. Kilroy is sitting on significant assets, but its ability to borrow more is capped by the declining value of office properties and higher market interest rates.
Kilroy is a business in a difficult transition where a high-quality property portfolio is being weighed down by a weak office market and rising development costs.
Leasing volume reached a six-year high in the fourth quarter of 2025, showing that there is still demand for premium space at the right price. This surge in activity suggests that while the office market is tough, Kilroy’s specific buildings are still able to win over tenants from lower-quality competitors.
Occupancy has fallen to 81.6%, a level that makes it difficult for the company to cover its fixed costs and dividends without depleting its cash reserves. If occupancy does not begin a steady climb back toward 90%, Kilroy may be forced to sell assets at a loss or cut its spending on new projects.
The West Coast office and life science market is a multibillion-dollar industry currently facing its most severe downturn in decades due to the rise of remote work. The traditional office market is a mature industry growing at less than 2% annually, with pricing power shifting heavily toward tenants. While the life science niche remains more resilient, the overall sector is defined by high barriers to entry due to land scarcity and zoning laws. Kilroy stands as a high-end niche player, but its concentration in tech-heavy cities like San Francisco makes it vulnerable to the specific hiring freezes and cost-cutting trends currently hitting that industry.
The competitive dynamic for premier office space has become a "flight to quality," where only the newest and best buildings can attract tenants. While the overall market is oversupplied, barriers to building new "trophy" assets are extremely high. This creates a bifurcated market where owners of older buildings are losing everything to owners of modern, sustainable space.
Alexandria Real Estate is the most dangerous threat because it dominates the life science sector that Kilroy is trying to grow into. Boston Properties also competes fiercely for the same large tech tenants in San Francisco and Seattle, often with more diverse geographic footprints that lower their risk. Kilroy is being squeezed by rivals who have either more specialized lab expertise or broader national diversification.
Kilroy is currently losing ground as its occupancy rate remains significantly below its historical levels and its peer group average. The company's 81.6% occupancy rate is a clear signal that it is struggling to defend its market share in a shrinking pool of tenants.
Kilroy’s narrow moat comes from its "intangible assets," specifically its portfolio of highly specialized buildings in prime West Coast locations that are nearly impossible to replicate. These properties are designed for the specific needs of tech and biotech firms, creating a form of switching cost because moving an entire lab or a high-tech headquarters is prohibitively expensive. However, this moat only works when there is a line of tenants waiting to get in.
The numbers tell a story of a moat that is failing to protect profits, as the company’s 2.8% ROIC is well below its cost of capital. High-quality assets should produce higher returns, but the current 18.4% vacancy rate suggests that Kilroy’s "trophy" buildings are being treated more like commodities by cost-conscious tenants. The lack of pricing power is visible in the flat revenue and declining earnings.
The forward verdict is that Kilroy’s moat is eroding as the structural shift to remote work permanently reduces the value of even the best office buildings. The single most important signal is the continued struggle to push occupancy back toward 90% without offering massive rent discounts.
FFO beat in Q4 2025 but occupancy remains low at 81.6% after repeated misses.
Sold $755M in assets to fund $192M Torrey Pines life science acquisition.
CEO took office in 2024; insider stake is growing but still relatively small.
Capital Allocation Track Record
Angela Aman is a proven real estate executive who was brought in to lead a difficult turnaround, and her strategy of "capital recycling" shows a disciplined focus on long-term survival. She has successfully sold nearly $800 million of older properties to fund a pivot into life science labs, which is a smarter bet than doubling down on traditional office space. However, her caliber is still being tested by a market that is moving against her, as the company has struggled to fill its vacant buildings fast enough to stop the decline in earnings.
The primary governance risk is that the company’s future depends entirely on management’s ability to execute this high-stakes pivot without a deep bench of life science expertise. While the board is independent, the strategy is a "person-key" bet on Aman’s vision for a smaller, more specialized Kilroy. If she were to leave before the life science projects are finished and leased, the company would be left with a half-completed portfolio and a massive amount of debt in a sector that few other buyers want to touch.
We expect revenue to grow from $1.1B in FY2026 to $1.2B in FY2031 (~2% CAGR), with EPS growing from $0.27 to $1.40 (~39% CAGR). Revenue grows slowly as new life science and tech office developments are completed and leased up in West Coast markets. Margins improve as the company moves past one-time restructuring costs and fills vacant space in its existing portfolio. EPS grows much faster than revenue because it is recovering from a very low base caused by temporary interest rate and leasing shocks. Operating margin expected to reach ~28% by FY2031.
Life science pivot replaces lost office rent with stable labs. If the Nautilus acquisition and other lab developments lease up quickly, Kilroy transforms into a biotech-focused landlord with more durable cash flows.
Large-scale tech hiring returns to West Coast hubs. A massive return-to-office movement by major tech tenants would immediately fill Kilroy’s 18.4% vacancy and restore its pricing power.
Asset sales at premium prices strengthen the balance sheet. Selling older office buildings for more than their book value would provide the cash needed to finish new developments without borrowing more.
Prolonged tech vacancy leads to permanent rent declines. If tech companies continue to shrink their office footprints, Kilroy will be forced to lower rents to keep tenants, permanently hurting margins.
Life science oversupply in San Diego and San Francisco. Too many developers building labs at once would lead to a "lab bubble" where rent prices crash just as Kilroy finishes its buildings.
Interest rates stay higher for longer, increasing debt costs. Kilroy’s development pipeline requires constant funding: if interest rates stay high, the cost to finish these projects will eat all remaining profit.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/FFO approach (Price to Funds From Operations) to determine fair value. FFO is the standard valuation metric for Real Estate Investment Trusts (REITs) because it adds back non-cash depreciation, which is a massive expense that artificially lowers the GAAP net income of property owners. For a company like Kilroy, FFO provides a much clearer picture of the cash available to pay dividends than traditional earnings per share.
Next year's projected FFO of $3.40 multiplied by an 11.0x multiple gives a per-share fair value of $37. An 11x multiple sits at the midpoint of office-heavy peers like Boston Properties (11x) and life-science leaders like Alexandria (14x), reflecting Kilroy's mixed portfolio of both asset types. We use a projected FY2027 FFO of $3.40 instead of the deterministic engine's $0.66 EPS because GAAP depreciation in the REIT sector makes the EPS figure an unreliable signal of true economic value.
Cross-checked with a Net Asset Value (NAV) analysis, we get $39 — within 5% of our $37 P/FFO answer, confirming the result. We estimated the value of the properties by applying a 7.5% capitalization rate (the rate of return an investor expects) to the portfolio’s expected net operating income, then subtracted the $4.7 billion in total debt. The resulting private-market value of the buildings, divided by 117.6 million shares, suggests the stock is currently trading almost exactly at the liquidation value of its real estate.
We're assuming Kilroy sustains a stabilized portfolio occupancy between 76% and 78% through FY2027. This matches management’s recent guidance and reflects the reality that while some tenants are leaving, the high quality (Class A) of Kilroy’s buildings provides a "flight to quality" floor that prevents occupancy from collapsing to broader market averages.
We're assuming that life science and lab space will contribute roughly 25% of Net Operating Income (NOI) by 2028. Kilroy has invested billions into projects like Kilroy Oyster Point, and current leasing momentum in the San Diego and South San Francisco markets suggests these assets will be the primary engine for cash flow growth as traditional office leases expire.
We're assuming Kilroy can successfully refinance or extend its upcoming debt maturities without a material spike in interest expense. The company recently recast its credit facilities and maintains a manageable 0.9x debt-to-equity ratio, which provides enough breathing room to wait for more favorable rates before issuing new long-term bonds.
The biggest risk is a "death spiral" in West Coast office occupancy where falling foot traffic leads to lower rents and higher vacancy in a self-reinforcing loop. This would likely compress the valuation multiple from 11x to 8x, knocking roughly $10 off the per-share fair value as investors price in a permanent loss of earnings power. Watch for occupancy rates in the San Francisco sub-portfolio dropping below 70% in the next two quarters.
Bear case ($28): Portfolio occupancy falls below 75% as major tech tenants fail to renew leases in San Francisco or Seattle; or The company is forced to cut its quarterly dividend to preserve cash for heavy redevelopment costs.
Bull case ($46): Occupancy in the life science (lab) segment reaches 95% while office demand stabilizes above 85%; or Capital markets ease, allowing Kilroy to sell older office assets at prices above their current book value.
Clearthesis wrote this report from 39 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on July 1, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning neutral because Kilroy's high office vacancy rate creates uncertainty about whether life science growth can save the bottom line. While the firm is pivoting to labs, an 18.4% vacancy rate in its portfolio forces a drop in expected 2026 profits that keeps investors cautious.
Optimists argue that the company is a unique way to gain high-yield exposure to the artificial intelligence boom in Silicon Valley. They believe that as AI companies expand, the demand for Kilroy's premier West Coast lab space will ultimately allow the firm to grow cash flow despite the broader slump in traditional office buildings.